IP Library › Granted Patent US 10,206,990
Granted Patent B2
US 10,206,990 · App. 15/447,598 · Granted Feb 19, 2019

Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer

Inventor: Ramila Philip (Ivyland, PA)
Assignee: Immunotope, Inc.
A61K39/0011A61K38/191A61K38/193A61K38/2006A61K38/208A61K38/2013A61K38/2046A61K38/2086C07K7/06C07K14/4748C07K14/70539A61K2039/55566A61K2039/572
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,206,990
App. No.
15/447,598
Granted
Feb 19, 2019
Kind
B2
Abstract

The present invention relates to compositions and methods for the prevention, treatment, and diagnosis of cancer, especially carcinomas, such as pancreatic carcinoma. The invention discloses peptides, polypeptides, and polynucleotides that can be used to stimulate a CTL response against pancreatic and other cancers.

Claims (12)

1. A method for treating tumor cells in a subject comprising:

(a) eliciting a CTL response against tumor cells presenting at least one epitopic peptide from a group of peptides consisting of SEQ ID NOS: 1 through 3 and SEQ ID NOS: 5 through 53 by administration of a sufficient amount of a composition containing at least one peptide from the group and a stabilizing agent; or

(b) stimulating an immune response in an immunologically competent animal, said composition consisting of at least one of SEQ ID NOS: 1 through 3 and SEQ ID NOS: 5 through 53 and a stabilizing agent capable of facilitating an immune response thereof.

2. The method of claim 1 , wherein said composition further comprises an adjuvant, optionally wherein said adjuvant is selected from the group consisting of complete Freund's adjuvant, incomplete Freund's adjuvant, Montanide ISA-51, LAG-3, aluminum phosphate, aluminum hydroxide, alum, and saponin.

3. The method of claim 1 , wherein said composition further comprises a cytokine, optionally wherein said cytokine is selected from the group consisting of IL-1, IL-2, IL-7, IL-12, IL-15, TNF, SCF and GM-CSF.

4. The method of claim 1 , wherein said composition further comprises a vehicle, optionally wherein said vehicle is selected from the group consisting of a liposome, nanoparticles, an immunostimulating complex (ISCOM), and slow-releasing particles.

5. The method of claim 4 , wherein said liposome comprises an emulsion, a foam, a micelle, an insoluble monolayer, a liquid crystal, phospholipid dispersion, or a lamellar layer.

6. The method of claim 1 (a), wherein said tumor cells are part of a carcinoma.

7. The method of claim 6 , wherein said tumor cells are part of an ovarian carcinoma.

8. A method for treating tumor cells in a subject comprising:

(a) eliciting a CTL response against tumor cells presenting at least one epitopic peptide from a group of peptides consisting of SEQ ID NOS: 1 through 3 and SEQ ID NOS: 5 through 53 by administration of a sufficient amount of a composition containing at least one peptide from the group linked through a non-conventional peptide bond to an additional peptide sequence and a stabilizing agent; or

(b) stimulating an immune response in an immunologically competent animal, said composition consisting of at least one of SEQ ID NOS: 1 through 3 and SEQ ID NOS: 5 through 53 and a stabilizing agent capable of facilitating an immune response thereof.

Continuity (4)
Division 14344048
Provisional Application 61533852 · Sep 13, 2011
Provisional Application 61611725 · Mar 16, 2012
Related Publication 20170173135A1 · Jun 22, 2017